Table 1.
Baseline characteristics according to TAC-IPV and RM/NRM status.
| Low-IPV/NRM(n = 452) | High-IPV/NRM(n = 375) | Low-IPV/RM(n = 106) | High-IPV/RM(n = 147) | P-value | |
|---|---|---|---|---|---|
| Donor factors | |||||
| Age (years) | 44.7 ± 12.4 | 45.0 ± 12.9 | 44.3 ± 12.5 | 44.6 ± 13.8 | 0.951 |
| Male sex (n, %) | 225 (49.8%) | 190 (50.7%) | 57 (53.8%) | 79 (53.7%) | 0.788 |
| BMI (kg/m2) | 23.6 ± 3.4 | 23.7 ± 3.4 | 23.7 ± 3.7 | 23.8 ± 3.7 | 0.929 |
| Transplant information | |||||
| Preemptive KT (n, %) | 98 (21.7%) | 82 (21.9%) | 19 (17.9%) | 35 (23.8%) | 0.734 |
| Deceased donor KT (n, %) | 154 (34.1%) | 140 (37.3%) | 37 (34.9%) | 42 (28.6%) | 0.301 |
| ABO-incompatible KT (n, %) | 69 (15.3%) | 56 (14.9%) | 13 (12.3%) | 26 (17.7%) | 0.384 |
| Previous history of KT (n, %) | 11 (2.4%) | 5 (1.3%) | 1 (0.9%) | 6 (4.1%) | 0.192 |
| PRA positive (n, %) | 157 (34.7%) | 115 (30.7%) | 29 (27.4%) | 47 (32.0%) | 0.411 |
| Cold ischemic time (min) | 188 ± 94 | 188 ± 74 | 204 ± 89 | 213 ± 84 | 0.318 |
| Mismatch number | 3.45 ± 1.55 | 3.43 ± 1.58 | 3.29 ± 1.62 | 3.48 ± 1.50 | 0.834 |
| Tacrolimus-related information | |||||
| Tacrolimus measurement frequency |
15.1 ± 2.9†§ | 15.7 ± 3.1*‡ | 14.9 ± 2.4†§ | 16.0 ± 3.7*‡ | <0.001 |
| TAC-C0-TWA (ng/mL) | 6.94 ± 1.22†‡§ | 6.50 ± 1.71*‡§ | 5.94 ± 1.59*†§ | 5.24 ± 1.42*†‡ | <0.001 |
| TWCV (%) | 22.7 ± 4.5†§ | 43.6 ± 13.3*‡ | 23.4 ± 4.5†§ | 41.6 ± 10.9*‡ | <0.001 |
| CDR (ng•mg/mL) | 2.16 ± 1.15‡§ | 2.13 ± 1.12‡§ | 0.82 ± 0.16*† | 0.80 ± 0.17*† | <0.001 |
| Recipient factors | |||||
| Age (years) | 48.6 ± 11.1§ | 47.0 ± 11.8§ | 45.7 ± 10.9 | 42.5 ± 11.6*† | <0.001 |
| Male sex (n, %) | 302 (66.8%)† | 206 (54.9%)*‡§ | 76 (71.7%)† | 89 (60.5%)† | 0.001 |
| BMI (kg/m2) | 23.2 ± 3.6 | 22.9 ± 3.5 | 23.8 ± 3.7 | 22.8 ± 3.6 | 0.032 |
| Cause of ESKD | |||||
| DM (n, %) | 96 (21.2%) | 76 (20.3%) | 26 (24.5%) | 24 (16.3%) | 0.426 |
| HTN (n, %) | 61 (13.5%) | 55 (14.7%) | 19 (17.9%) | 19 (12.9%) | 0.649 |
| CGN (n, %) | 154 (34.1%) | 133 (35.5%) | 36 (34.0%) | 52 (35.4%) | 0.972 |
| Others (n, %) | 59 (13.1%) | 41 (10.9%) | 9 (8.5%) | 18 (12.2%) | 0.552 |
| Unknown (n, %) | 82 (18.1%) | 70 (18.7%) | 16 (15.1%) | 34 (23.1%) | 0.408 |
| Dialysis information | |||||
| Hemodialysis (n, %) | 275 (60.8%) | 233 (62.1%) | 68 (64.2%) | 80 (54.4%) | 0.350 |
| Peritoneal dialysis (n, %) | 79 (17.5%) | 60 (16.0%) | 19 (17.9%) | 32 (21.8%) | 0.487 |
| Dialysis vintage (months) | 46.0 ± 55.8 | 43.7 ± 49.4 | 37.1 ± 49.5 | 37.0 ± 52.1 | 0.143 |
| Induction regimen | |||||
| Antithymocyte globulin (n, %) |
91 (20.1%) | 60 (16.0%) | 16 (15.1%) | 16 (10.9%) | 0.055 |
| Basiliximab (n, %) | 361 (79.9%)§ | 318 (84.8%) | 92 (86.8%) | 134 (91.2%)* | 0.007 |
Continuous variables are shown as mean ± standard deviation and categorical variables are shown as proportions.†P <0.0083 versus high-IPV/NRM group§P <0.0083 versus high-IPV/RM group.
BMI, body mass index; CDR, concentration-to-dose ratio; CGN, clinical glomerulonephritis; DM, diabetes mellitus; ESKD, end-stage kidney disease; HTN, hypertension; IPV, intra-patient variability; KT, kidney transplantation; NRM, non-rapid metabolizer; PRA, panel reactive antibody; RM, rapid metabolizer; TAC, tacrolimus; TAC-C0, tacrolimus trough level; TWA, time-weighted average; TWCV, time-weighted coefficient variation.